Back

Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories - findings from the EMPEROR-Pooled

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: How to treat HFpEF in 2022 and beyond Comorbidities ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

3 More presentations in this session

Presentation thumbnail
Treating HFpEF: State of the art 2022
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Digoxin improves systolic cardiac function in patients with AF and HFpEF: the RATE-AF randomised trial
Doctor K. Bunting (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
How to treat HFpEF in 2022 and beyond
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
What value do SGLT2 inhibitors offer to patients hospitalised for heart failure?
thumbnail
Congress Presentation
The SGLT2 inhibitor empagliflozin in patients hospitalised for acute heart failure: a multinational randomised trial
thumbnail
Congress Presentation
CONFIDENCE: Results by KDIGO risk category

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources